People living with peanut allergies deal with the daily struggle of having to avoid peanut products at all costs or they risk experiencing a severe allergic reaction...but a new treatment could possibly change all of that. A study published in the New England Journal of Medicine Sunday found that AR101, a peanut-derived immunotherapy drug, allowed participants ages 4 to 17 to tolerate at least 600 mg of peanut protein (which is about two whole peanut kernels).